Acurx Pharmaceuticals Inc ACXP.OQ ACXP.O is expected to report resultson March 13 for the period ending December 31 2025
LSEG's mean analyst estimate for Acurx Pharmaceuticals Inc is for a loss of $1.01 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $30.50, about 951.7% above its last closing price of $2.90
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -1.44 | -1.31 | -1.23 | Beat | 6.1 |
Jun. 30 2025 | -2.25 | -2.27 | -1.89 | Beat | 16.6 |
Mar. 31 2025 | -3.15 | -3.00 | -2.20 | Beat | 26.7 |
Dec. 31 2024 | -3.60 | -3.20 | Beat | 11.1 | |
Sep. 30 2024 | -4.60 | -4.00 | -3.40 | Beat | 15 |
Jun. 30 2024 | -4.32 | -4.40 | -5.20 | Missed | -18.2 |
Mar. 31 2024 | -4.80 | -4.80 | -5.60 | Missed | -16.7 |
Dec. 31 2023 | -5.20 | -7.40 | Missed | -42.3 |
This summary was machine generated March 11 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)